SwanBio Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
SwanBio Therapeutics was a gene-therapy company founded in 2018 in Bala Cynwyd, Pennsylvania, focused on genetically defined neurological disorders. Its lead program, SBT101, was an AAV-based gene therapy for adrenomyeloneuropathy (AMN), a progressive disease caused by ABCD1 gene mutations affecting about 10,000 people in the US and Europe. SBT101 received FDA Fast Track and Orphan Drug designations and entered a Phase 1/2 trial in 2022. In June 2024 the company was acquired and merged with Freeline Therapeutics to form Spur Therapeutics.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
SwanBio Therapeutics is founded in Pennsylvania by Syncona as a gene-therapy company for genetically defined neurological disorders.
- Peak funding round
The company raises a $56 million Series B, taking total funding to about $133 million, and starts a Phase 1/2 trial of SBT101 in adrenomyeloneuropathy.
- Acquisition
Freeline Therapeutics acquires SwanBio in June 2024; the two Syncona portfolio companies merge to form Spur Therapeutics at a combined valuation of about £104.7 million.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.